Evidence map›Paper›PMID 42819300›Full record

ArticleJACS Au2026

Development of High-Efficiency Mitochondrial Protease Targeting Chimeras (MtPTACs) for Targeted Degradation of POLRMT and Beyond.

Cong Chen, Lihua Liu, Xinnan Li, Yuning Shi, Jieya Zhou, Lijuan Huang, Liyue Zeng, Dazhi Feng, Yunyue Wang, Xinyang Nie and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cong ChenDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Lihua LiuDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Xinnan LiDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Yuning ShiDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Jieya ZhouDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Lijuan HuangDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Liyue ZengDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Dazhi FengDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Yunyue WangDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Xinyang NieDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Quanyi HuangDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Yifei WuDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Shaokang PangDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.
Jinyi XuDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.ORCID https://orcid.org/0000-0002-1961-0402
Shengtao XuDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.ORCID https://orcid.org/0000-0002-5705-6377
Hong YaoDepartment of Medicinal Chemistry, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P. R. China.ORCID https://orcid.org/0000-0002-9594-9598

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the broad success of targeted protein degradation (TPD), achieving efficient degradation within mitochondria remains a challenge. Herein, we report a highly active degrader targeting human mitochondrial RNA polymerase (POLRMT) based on the Mitochondrial Protease Targeting Chimeras (MtPTACs) strategy. The lead compound,

Indexed as

Mitochondrial ClpP proteaseMitochondrial Protease Targeting Chimeras (MtPTACs)OXPHOSPOLRMTTargeted protein degradation

Identifiers

PMID42819300
PMCPMC13625557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.